



College of Pharmacists
of British Columbia

DRUG SCHEDULES REGULATION CHANGES – DECEMBER 2018 AND JANUARY 2019

The following amendments to the Schedules to the Drug Schedules Regulation made under the *Pharmacy Operations and Drug Scheduling Act* came into force, or will come into force, on the date indicated below. The amendments may not yet be reflected on the Drug Schedules Regulation published by the British Columbia government on the BC Laws website (www.bclaws.com).

OLD ENTRY		NEW ENTRY		IN FORCE DATE
	None	1	Codeine, except (a) when prescribed as a single entity, (b) when included in a preparation containing 60 mg or more per dosage unit, or (c) in preparations exempted from the Regulations to the Controlled Drugs and Substances Act (Canada)	January 22, 2019 (Expected)
	None	1	Lisdexamfetamine dimesylate	January 22, 2019 (Expected)
1	Nicotine and its salts, for human use, except (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit	1	Nicotine or its salts, for human use, except (a) in natural substances; (b) in the form of a chewing gum containing 4 milligrams or less of nicotine per dosage unit, (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day, (d) in a form to be administered into the oral cavity by means of a non-active device (one that operates on energy generated by the human body or by gravity) that delivers 4 mg or less of nicotine per dose for buccal absorption, or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit	January 22, 2019 (Expected)

OLD ENTRY		NEW ENTRY	IN FORCE DATE
	None	<p>1 Phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids, except</p> <p>(a) derivatives of cannabis as defined in subsection 2(1) of the Cannabis Act (Canada) that are exempt from the application of that Act under the Industrial Hemp Regulations (Canada) and that do not contain an isolated or concentrated phytocannabinoid or a synthetic duplicate of that phytocannabinoid,</p> <p>(b) anything referred to in Schedule 2 to the Cannabis Act (Canada) that contains no more than 10 µg/g delta-9-tetrahydrocannabinol and that does not contain an isolated or concentrated phytocannabinoid or a synthetic duplicate of that phytocannabinoid, or</p> <p>(c) anything referred to in the Cannabis Exemption (Food and Drugs Act) Regulations (Canada) that is exempt from the application of the Food and Drugs Act (Canada)</p>	December 7, 2018
	None	<p>1 Synthetic cannabinoid receptor type-1 agonists, their salts, derivatives, isomers, and salts of derivatives and isomers, as listed in the schedules to the Controlled Drugs and Substances Act (Canada) and the Narcotic Control Regulations (Canada)</p>	December 2018